Skip to content
Limited human dataNot FDA approved

CJC-1295 side effects

Also known as: CJC-1295 with DAC · DAC:GRF · CJC-1295 without DAC · CJC no DAC · Mod GRF 1-29 · Tetrasubstituted GRF 1-29

Updated 25 sources

10 side effects reported for CJC-1295: 3 from studies and labels, 7 from users and guides. 2 come with the ways people manage them.

CJC-1295 overview

Side effects reported in studies and labels

Rates as each trial or label states them. A rate from one trial does not carry over to research-grade vials or other doses.

From trials and regulators3

Clinical studies and regulatory documents.

  • Overall tolerability with DAC in trials

    No serious adverse reactions in healthy adults; relatively well tolerated, especially at 30 or 60 mcg/kg. Event rates are in the full paper, not the abstract

  • Faster heart rate

    FDA lists serious adverse events including increased heart rate; a 2026 review describes vasodilatory reactions and tachycardia reports

  • Raised baseline GH with DAC

    Continuous stimulation raised trough GH 7.5-fold while normal pulses were kept. The long-term meaning is unknown

    How people manage it

    • Guides use this to argue for the no-DAC version.

Side effects users and guides report

What people post and what dosing guides list. These are reports, not measured rates.

From users and guides7

Community reports, competitor and vendor guides, media.

  • Flushing or warmth after the shot

    Reported by guides, mostly in weeks 1 to 2

  • Water retention

    Reported for the first 2 to 3 weeks. One guide says 10 to 30% of users, with no source for that figure

  • Hunger

    Reported by guides, more when paired with ipamorelin

  • Headache

    Reported early, in weeks 1 to 2

  • Hand numbness or carpal-tunnel-like symptoms

    Reported by guides; carpal-tunnel-like symptoms described as rare

  • Injection-site irritation

    Reported by guides

  • High IGF-1 or rising blood sugar

    A guide-level watch item for DAC, not a reported rate

    How people manage it

    • Drop DAC to 0.5 mg a week if IGF-1 runs high.
    • Stop or reassess if fasting glucose is above 105 mg/dL or HbA1c is rising.

How much is known

Limited human data

With DAC: Phase 1 and 2 trials. 60 or 90 mcg/kg raised mean GH 46% and IGF-1 45% at one week, with no difference between doses. IGF-1 stayed above baseline up to 28 days after multiple doses. Without DAC: essentially uncharacterized in humans.

Sources for these side effects

7 sources, each checked by date. Record updated Oct 23, 2026. Numbers are restated in our own words and labelled by where they came from.

Regulatory1

  1. Certain bulk drug substances, safety risksFDA · checked Oct 23, 2026

Competitor guide3

  1. CJC-1295PeptidesExplorer · checked Oct 23, 2026
  2. CJC-1295 no DAC dosage guideBodyHackGuide · checked Oct 23, 2026
  3. CJC-1295 DAC dosage guideBodyHackGuide · checked Oct 23, 2026

Back to the full CJC-1295 page for dosing, the vial chart and storage.